source
- Axoltis Phase 2 ALS Trial Fails Primary Endpoint Though Shows Some Secondary TrendsAxoltis Pharma reported that its phase 2 study of the synthetic peptide NX210c in amyotrophic lateral sclerosis did not meet its primary goal. The double‑blind, randomized trial enrolled 82 French…
- Novo rebrands, drops 'Nordisk' to become simply 'Novo' in market pushNovo Nordisk announced a major rebranding that will see the company drop the "Nordisk" part of its everyday brand. The legal name Novo Nordisk A/S remains unchanged, but the company will be known s…